Sparks - Immix Biopharma

Immix has reported an independently reviewed 89% complete response rate (40/45) for NXC-201 in the fully enrolled NEXICART-2 study of relapsed or refractory amyloid light chain amyloidosis. Of the 25 more recently assessed patients, 21 have achieved complete response and four have no detectable residual disease in their bone marrow. If all four convert to complete response, as earlier patients with this marker did, the overall rate would rise to 98% (44/45). The current 89% is below the 95% (19/20) reported for the first patients in May, although it now covers the full study population. No relapses have been observed among patients in complete response or with residual disease negativity, and the company reports no neurotoxicity or enterocolitis.

The final readout and a US biologics licence application are planned for mid-2027, following earlier guidance for Q326 top-line results and a subsequent filing. Alongside the data, Immix priced 11.36m new shares at $11 each for $125m gross, with closing expected on 30 September and net proceeds intended for NXC-201 development and corporate purposes. On completion, the financing would strengthen resources ahead of regulatory filing, adding to the $232.1m in cash and short-term investments reported at the end of June.